Boditech Med and HLB LifeCare Sign MOU to Develop AI-Based Chronic Disease Diagnostics
- Aimed at early detection and improved accessibility through personalized diagnostics
- Joint development of new biomarkers and rapid in vitro diagnostic products
- Convergence of digital healthcare and diagnostics to reshape chronic disease management
Boditech Med, a global point-of-care diagnostic company, announced that it has signed a strategic Memorandum of Understanding (MOU) with HLB LifeCare, a digital healthcare firm, to jointly develop AI-based personalized diagnostic solutions for chronic diseases, including diabetes.
Under the agreement, the two companies will collaborate across the full product lifecycle—covering:
• Discovery of new biomarkers for chronic diseases
• Development of AI-driven disease prediction algorithms
• Co-development of point-of-care diagnostic tests using Boditech Med’s AFIAS and ichroma™ platforms
• Clinical validation, regulatory approvals, and product commercialization
HLB LifeCare specializes in the collection of personal health data through continuous glucose monitors (CGMs), smartwatch technologies, medical big data cohorts, and integration with hospital EMR systems. Using AI, the company aims to analyze patterns in blood glucose, lifestyle habits, and risk factors to predict the onset of diabetes and related complications, such as retinopathy, kidney disease, and cardiovascular conditions.
Boditech Med brings its advanced in vitro diagnostic (IVD) technologies to the collaboration. Its AFIAS and ichroma™ platforms are already in use for rapid and accurate testing across a wide range of disease areas, including infectious diseases, endocrine disorders, and cardiovascular conditions. These platforms are suitable for diverse settings—from hospitals and clinics to pharmacies, community health centers, and even at-home environments—making them well-aligned with digital healthcare integration.
Together, the companies plan to accelerate the development of a hybrid diagnostic model that transcends hospital-based testing by enabling real-time, predictive diagnostics embedded into daily life. The joint solution is also expected to support low-resource regions where chronic disease prevalence is high and access to healthcare is limited.
Eui-yeol Choi, CEO of Boditech Med, stated:
“Personalized diagnostics that reflect an individual’s lifestyle and health status will be transformative in managing chronic diseases. Through this collaboration, we aim to make it easier and faster for patients to monitor and manage their health with confidence.”